NasdaqCM - Delayed Quote USD

ENDRA Life Sciences Inc. (NDRA)

Compare
4.5400 -0.7600 (-14.34%)
At close: November 15 at 4:00 PM EST
4.5000 -0.04 (-0.88%)
Pre-Market: 4:22 AM EST
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
9,598.2360
10,520.7350
13,157.5590
11,498.3050
11,501.9170
Operating Income
-9,598.2360
-10,520.7350
-13,157.5590
-11,498.3050
-11,501.9170
Net Non Operating Interest Income Expense
--
--
--
--
-232.4260
Other Income Expense
33.0110
460.4850
-21.5330
267.0550
8.8420
Pretax Income
-9,565.2250
-10,060.2500
-13,179.0920
-11,231.2500
-11,725.5010
Net Income Common Stockholders
-9,565.2250
-10,060.2500
-13,179.0920
-11,352.3210
-12,121.0520
Diluted NI Available to Com Stockholders
-9,565.2250
-10,060.2500
-13,179.0920
-11,352.3210
-12,121.0520
Basic EPS
-32.00
-79.00
-228.00
-280.00
-630.00
Diluted EPS
-32.00
-79.00
-228.00
-280.00
-630.00
Basic Average Shares
271.4380
127.2750
57.8250
40.9220
19.1920
Diluted Average Shares
271.4380
127.2750
57.8250
40.9220
19.1920
Total Operating Income as Reported
-9,598.2360
-10,520.7350
-13,157.5590
-11,498.3050
-11,501.9170
Total Expenses
9,598.2360
10,520.7350
13,157.5590
11,498.3050
11,501.9170
Net Income from Continuing & Discontinued Operation
-9,565.2250
-10,060.2500
-13,179.0920
-11,231.2500
-11,725.5010
Normalized Income
-9,565.2250
-10,060.2500
-13,179.0920
-11,539.8500
-11,725.5010
Interest Expense
--
--
--
--
232.4260
Net Interest Income
--
--
--
--
-232.4260
EBIT
-9,598.2360
-10,520.7350
-13,157.5590
-11,498.3050
-11,493.0750
EBITDA
-9,360.7400
-10,245.2840
-12,923.3010
-11,273.8900
-11,327.8260
Reconciled Depreciation
237.4960
275.4510
234.2580
224.4150
165.2490
Net Income from Continuing Operation Net Minority Interest
-9,565.2250
-10,060.2500
-13,179.0920
-11,231.2500
-11,725.5010
Total Unusual Items Excluding Goodwill
--
--
--
308.6000
--
Total Unusual Items
--
--
--
308.6000
--
Normalized EBITDA
-9,360.7400
-10,245.2840
-12,923.3010
-11,582.4900
-11,327.8260
12/31/2020 - 6/30/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers